Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
letter
. 1988 May;80(5):565–576.

Update in Cancer Chemotherapy: Genitourinary Tract Cancer, Part 5: Ovarian Cancer

Jane C Wright
PMCID: PMC2625767  PMID: 3047411

Abstract

An update of the state of the art of cancer chemotherapeutic treatment of genitourinary tract cancer is described in this multi-part series: included are cancers of the kidney, bladder, prostate, testicle, ovary, uterus, vulva, and gestational trophoblastic neoplasms. Part 5 is a review of treatments for cancer of the ovary.

Ovarian cancer is the leading cause of gynecologic cancer deaths and the fourth most frequent cause of death from cancer in women in the United States. Ovarian carcinoma is a classical “hidden” neoplasm of the abdomen and, as such, is insidious in its onset. Combination chemotherapy and cytoreductive surgery, however, have provided improved survival for patients with ovarian cancer. As dosage schedules and other refinements are made, the overall outlook for patients with ovarian cancer is promising.

Full text

PDF
565

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Moon T. E., Stephens R. A., Wilson H., Oishi N., Hilgers R. D., O'Toole R., Thigpen J. T. Randomized study of chemoimmunotherapy for advanced ovarian carcinoma: a preliminary report of a Southwest Oncology Group study. Cancer Treat Rep. 1979 Feb;63(2):325–331. [PubMed] [Google Scholar]
  2. Aure J. C., Hoeg K., Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol. 1971 Jan;37(1):1–9. [PubMed] [Google Scholar]
  3. BURNS B. C., Jr, RUTLEDGE F., GALLAGER H. S. Phenylalanine mustard in the palliative management of carcinoma of the ovary. Obstet Gynecol. 1963 Jul;22:30–37. [PubMed] [Google Scholar]
  4. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  5. Beck R. E., Boyes D. A. Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide. Can Med Assoc J. 1968 Mar 16;98(11):539–541. [PMC free article] [PubMed] [Google Scholar]
  6. Borchert P., Wattenberg L. W. Inhibition of macromolecular binding of benzo(a)pyrene and inhibition of neoplasia by disulfiram in the mouse forestomach. J Natl Cancer Inst. 1976 Jul;57(1):173–179. doi: 10.1093/jnci/57.1.173. [DOI] [PubMed] [Google Scholar]
  7. Bramwell V. H., Crowther D., O'Malley S., Swindell R., Johnson R., Cooper E. H., Thatcher N., Howell A. Activity of JM9 in advanced ovarian cancer: a phase I-II trial. Cancer Treat Rep. 1985 Apr;69(4):409–416. [PubMed] [Google Scholar]
  8. Bruckner H. W., Cohen C. J., Wallach R. C., Kabakow B., Deppe G., Greenspan E. M., Gusberg S. B., Holland J. F. Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy. Cancer Treat Rep. 1978 Apr;62(4):555–558. [PubMed] [Google Scholar]
  9. Bush R. S., Allt W. E., Beale F. A., Bean H., Pringle J. F., Sturgeon J. Treatment of epithelial carcinoma of the ovary: operation, irradiation, and chemotherapy. Am J Obstet Gynecol. 1977 Apr 1;127(7):692–704. doi: 10.1016/0002-9378(77)90241-1. [DOI] [PubMed] [Google Scholar]
  10. Creasman W. T., Gall S. A., Blessing J. A., Schmidt H. J., Abu-Ghazaleh S., Whisnant J. K., DiSaia P. J. Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study. Cancer Treat Rep. 1979 Feb;63(2):319–323. [PubMed] [Google Scholar]
  11. Decker D. G., Fleming T. R., Malkasian G. D., Jr, Webb M. J., Jeffries J. A., Edmonson J. H. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol. 1982 Oct;60(4):481–487. [PubMed] [Google Scholar]
  12. Decker D. G., Mussey E., Malkasian G. D., Jr, Johnson C. E. Cyclophosphamide in the treatment of ovarian cancer. Clin Obstet Gynecol. 1968 Jun;11(2):382–400. doi: 10.1097/00003081-196806000-00001. [DOI] [PubMed] [Google Scholar]
  13. Dembo A. J., Bush R. S., Beale F. A., Bean H. A., Pringle J. F., Sturgeon J. F. The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentations. Cancer Treat Rep. 1979 Feb;63(2):249–254. [PubMed] [Google Scholar]
  14. Edmonson J. H., Fleming T. R., Decker D. G., Malkasian G. D., Jorgensen E. O., Jefferies J. A., Webb M. J., Kvols L. K. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treat Rep. 1979 Feb;63(2):241–247. [PubMed] [Google Scholar]
  15. Ehrlich C. E., Einhorn L., Williams S. D., Morgan J. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treat Rep. 1979 Feb;63(2):281–288. [PubMed] [Google Scholar]
  16. Greene M. H., Boice J. D., Jr, Greer B. E., Blessing J. A., Dembo A. J. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med. 1982 Dec 2;307(23):1416–1421. doi: 10.1056/NEJM198212023072302. [DOI] [PubMed] [Google Scholar]
  17. Griffiths C. T., Parker L. M., Fuller A. F., Jr Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979 Feb;63(2):235–240. [PubMed] [Google Scholar]
  18. Johnsson J. E., Tropé C., Mattsson W., Grundsell H., Aspegren K., Könyves I. Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma. Cancer Treat Rep. 1979 Mar;63(3):421–424. [PubMed] [Google Scholar]
  19. Keettel W. C., Pixley E. E., Buchsbaum H. J. Experience with peritoneal cytology in the management of gynecologic malignancies. Am J Obstet Gynecol. 1974 Sep 15;120(2):174–182. doi: 10.1016/0002-9378(74)90359-7. [DOI] [PubMed] [Google Scholar]
  20. Legha S. S., Slavik M., Carter S. K. Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer. 1976 Jul;38(1):27–35. doi: 10.1002/1097-0142(197607)38:1<27::aid-cncr2820380106>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  21. MASTERSON J. G., CALAME R. J., NELSON J. A clinical study on the use of chlorambucil in the treatment of cancer of the ovary. Am J Obstet Gynecol. 1960 May;79:1002–1007. doi: 10.1016/0002-9378(60)90697-9. [DOI] [PubMed] [Google Scholar]
  22. MUNNELL E. W., JACOX H. W., TAYLOR H. C., Jr Treatment and prognosis in cancer of the ovary, with a review of a new series of 143 cases treated in the years 1944-1951. Am J Obstet Gynecol. 1957 Dec;74(6):1187–1200. doi: 10.1016/0002-9378(57)90004-2. [DOI] [PubMed] [Google Scholar]
  23. Neijt J. P., van Lindert A. C., Vendrik C. P., Roozendaal K. J., Struyvenberg A., Pinedo H. M. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future. Neth J Med. 1979;22(2):38–44. [PubMed] [Google Scholar]
  24. Ozols R. F., Garvin A. J., Costa J., Simon R. M., Young R. C. Histologic grade in advanced ovarian cancer. Cancer Treat Rep. 1979 Feb;63(2):255–263. [PubMed] [Google Scholar]
  25. Parker L. M., Griffiths C. T., Yankee R. A., Canellos G. P., Gelman R., Knapp R. C., Richman C. M., Tobias J. S., Weiner R. S., Frei E., 3rd Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer. 1980 Aug 15;46(4):669–674. doi: 10.1002/1097-0142(19800815)46:4<669::aid-cncr2820460407>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  26. Parker L. M., Griffiths C. T., Yankee R. A., Knapp R. C., Canellos G. P. High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study. Cancer Treat Rep. 1979 Feb;63(2):275–279. [PubMed] [Google Scholar]
  27. Perez C. A., Walz B. J., Lacobson P. L. Radiation therapy in the management of carcinoma of the ovary. Natl Cancer Inst Monogr. 1975 Oct;42:119–125. [PubMed] [Google Scholar]
  28. Piver M. S., Barlow J. J., Lele S. B., Higby D. J. cis-Dichlorodiammineplatinum(II) as third-line chemotherapy in advanced ovarian adenocarcinoma. Cancer Treat Rep. 1978 Apr;62(4):559–560. [PubMed] [Google Scholar]
  29. Piver M. S., Barlow J. J., Lele S. B. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol. 1978 Jul;52(1):100–104. [PubMed] [Google Scholar]
  30. RUNDLES R. W., BARTON W. B. Triethylene melamine in the treatment of neoplastic disease. Blood. 1952 May;7(5):483–507. [PubMed] [Google Scholar]
  31. Radice P. A., Bunn P. A., Jr, Ihde D. C. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep. 1979 Aug;63(8):1231–1239. [PubMed] [Google Scholar]
  32. Reimer R. R., Hoover R., Fraumeni J. F., Jr, Young R. C. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977 Jul 28;297(4):177–181. doi: 10.1056/NEJM197707282970402. [DOI] [PubMed] [Google Scholar]
  33. SYKES M. P., RUNDLES R. W., PIERCE V. K., KARNOFSKY D. A. Triethylene melamine in the management of far advanced ovarian cancer. Surg Gynecol Obstet. 1955 Aug;101(2):133–140. [PubMed] [Google Scholar]
  34. Smith J. P., Rutledge F. Chemotherapy in the treatment of cancer of the ovary. Am J Obstet Gynecol. 1970 Jul 1;107(5):691–703. doi: 10.1016/s0002-9378(16)33987-4. [DOI] [PubMed] [Google Scholar]
  35. Smith J. P., Rutledge F., Wharton J. T. Chemotherapy of ovarian cancer. New approaches to treatment. Cancer. 1972 Dec;30(6):1565–1571. doi: 10.1002/1097-0142(197212)30:6<1565::aid-cncr2820300623>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  36. Vogl S. E., Berenzweig M., Kaplan B. H., Moukhtar M., Bulkin W. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979 Feb;63(2):311–317. [PubMed] [Google Scholar]
  37. Vogl S. E., Pagano M., Davis T. E., Einhorn N., Tunca J. C., Kaplan B. H., Arseneau J. C. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy. Cancer Treat Rep. 1982 Jun;66(6):1285–1290. [PubMed] [Google Scholar]
  38. Wallach R. C., Blinick G. The second look operation for carcinoma of the ovary. Surg Gynecol Obstet. 1970 Dec;131(6):1085–1089. [PubMed] [Google Scholar]
  39. Wiltshaw E., Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976 Jan;60(1):55–60. [PubMed] [Google Scholar]
  40. Young R. C., Chabner B. A., Hubbard S. P., Fisher R. I., Bender R. A., Anderson T., Simon R. M., Canellos G. P., DeVita V. T., Jr Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261–1266. doi: 10.1056/NEJM197812072992301. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES